Frontiers of Science: Prof. Carlos L. Arteaga
Aika
3.10.2024 klo 12.00 - 13.00
Frontiers of Science
October 3rd at 12:00
Onsite event
in Presidentti auditorium, BioCity
Prof. Carlos L. Arteaga, UTSW Harold C. Simmons Comprehensive Cancer Center, USA
Are we curing estrogen receptor positive (ER+) breast cancer?
Host: Klaus Elenius (klaele@utu.fi)
Coffee and sandwich at 11:45, first come first served!
Six PhD researchers and early-career postdocs are welcome to have a lunch and discuss with Prof. Arteaga after the seminar. This is a great possibility to learn hosting skills in a friendly environment and create connections for future. Everyone is welcome to join, BioCity Turku will offer the lunch.
If you got interested, please send an email to biocityturku@bioscience.fi
The Arteaga Laboratory has a longstanding interest in understanding the molecular pathways that drive breast cancer progression and influence response to therapies. Their focus is on translational breast cancer research, aimed at developing therapeutic strategies and identifying biomarkers of drug sensitivity and resistance. The Arteaga Laboratory incorporates molecular profiling (next-gen DNA/RNA sequencing) of primary tumors, biopsies of metastases, and plasma tumor DNA, high-throughput CRISPR and gain-of-function ORF screens, and mechanistic studies using breast cancer cell lines, cell line-derived xenografts, and patient-derived organoids and xenografts, to use insights from the laboratory to guide clinical trials. Dr. Arteaga is an internationally recognized expert in breast cancer with more than 350 publications in the areas of oncogenes and breast tumor initiation and progression, targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer.
ed publications
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, … , Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. 2024. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nat Commun. 15(1):2287. doi: 10.1038/s41467-024-46495-2.
Marín A, Mamun AA, Patel H, Akamatsu H, Ye D, Sudhan DR, Eli L, Marcelain K, Brown BP, Meiler J, Arteaga CL, Hanker AB. 2023. Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer. Cancer Res. 83(18):3145-3158. doi: 10.1158/0008-5472.CAN-22-3617
Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, Kim G, Sudhan DR, Mendiratta S, González Ericsson PI, Balko JM, Lee J, Barnes S, Malladi VS, Tabrizi S, Reddy SM, Yum S, Chang CW, Hutchinson KE, Yost SE, Yuan Y, Chen ZJ, Fu YX, Hanker AB, Arteaga CL. 2022. Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. Cancer Immunol Res. 10(7):829-843. doi: 10.1158/2326-6066.CIR-21-0826.
Hanker AB, Sudhan DR, Arteaga CL. 2020. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell 37(4):496-513. doi: 10.1016/j.ccell.2020.03.009.
General information
• You can download and save all the autumn 2024 FoS-seminars to your calendar from here: https://seafile.utu.fi/d/44a70f80ac1e46a9ad0a/
• Registration is not needed, participation list is circulated in the audience
• If you are a student and later wish to get a certificate of attendance from the Frontier of Science seminars, print out the seminar diary and after the seminar ask the BioCity coordinator to sign it https://seafile.utu.fi/d/44a70f80ac1e46a9ad0a/
• Please note that any audio or video recording of the seminars is strictly forbidden.
• Autumn 2024 image credits to Mia Åstrand: Details of the Bacteroides fragilis VgrG protein (PDB ID: 8GRA). Image created in the PyMOL Molecular Graphics System, Version 2.5 Schrödinger, LLC.
October 3rd at 12:00
Onsite event
in Presidentti auditorium, BioCity
Prof. Carlos L. Arteaga, UTSW Harold C. Simmons Comprehensive Cancer Center, USA
Are we curing estrogen receptor positive (ER+) breast cancer?
Host: Klaus Elenius (klaele@utu.fi)
Coffee and sandwich at 11:45, first come first served!
Six PhD researchers and early-career postdocs are welcome to have a lunch and discuss with Prof. Arteaga after the seminar. This is a great possibility to learn hosting skills in a friendly environment and create connections for future. Everyone is welcome to join, BioCity Turku will offer the lunch.
If you got interested, please send an email to biocityturku@bioscience.fi
The Arteaga Laboratory has a longstanding interest in understanding the molecular pathways that drive breast cancer progression and influence response to therapies. Their focus is on translational breast cancer research, aimed at developing therapeutic strategies and identifying biomarkers of drug sensitivity and resistance. The Arteaga Laboratory incorporates molecular profiling (next-gen DNA/RNA sequencing) of primary tumors, biopsies of metastases, and plasma tumor DNA, high-throughput CRISPR and gain-of-function ORF screens, and mechanistic studies using breast cancer cell lines, cell line-derived xenografts, and patient-derived organoids and xenografts, to use insights from the laboratory to guide clinical trials. Dr. Arteaga is an internationally recognized expert in breast cancer with more than 350 publications in the areas of oncogenes and breast tumor initiation and progression, targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer.
ed publications
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, … , Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. 2024. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nat Commun. 15(1):2287. doi: 10.1038/s41467-024-46495-2.
Marín A, Mamun AA, Patel H, Akamatsu H, Ye D, Sudhan DR, Eli L, Marcelain K, Brown BP, Meiler J, Arteaga CL, Hanker AB. 2023. Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer. Cancer Res. 83(18):3145-3158. doi: 10.1158/0008-5472.CAN-22-3617
Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, Kim G, Sudhan DR, Mendiratta S, González Ericsson PI, Balko JM, Lee J, Barnes S, Malladi VS, Tabrizi S, Reddy SM, Yum S, Chang CW, Hutchinson KE, Yost SE, Yuan Y, Chen ZJ, Fu YX, Hanker AB, Arteaga CL. 2022. Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. Cancer Immunol Res. 10(7):829-843. doi: 10.1158/2326-6066.CIR-21-0826.
Hanker AB, Sudhan DR, Arteaga CL. 2020. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell 37(4):496-513. doi: 10.1016/j.ccell.2020.03.009.
General information
• You can download and save all the autumn 2024 FoS-seminars to your calendar from here: https://seafile.utu.fi/d/44a70f80ac1e46a9ad0a/
• Registration is not needed, participation list is circulated in the audience
• If you are a student and later wish to get a certificate of attendance from the Frontier of Science seminars, print out the seminar diary and after the seminar ask the BioCity coordinator to sign it https://seafile.utu.fi/d/44a70f80ac1e46a9ad0a/
• Please note that any audio or video recording of the seminars is strictly forbidden.
• Autumn 2024 image credits to Mia Åstrand: Details of the Bacteroides fragilis VgrG protein (PDB ID: 8GRA). Image created in the PyMOL Molecular Graphics System, Version 2.5 Schrödinger, LLC.